本帖最后由 老马 于 2013-3-13 13:43 编辑
; `0 P$ a- n5 l$ i. I/ j! y6 a, L L8 y0 y4 L6 t/ j
健择（吉西他滨）+顺铂+阿瓦斯汀
9 y6 A% _4 ^, ]0 O! |- B0 R' w Gemzar +Cisplatin + Avastin
0 l. O' P, Z M8 w- mhttp://annonc.oxfordjournals.org/content/21/9/1804.full9 w' b1 H2 ^7 e4 J
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 3 W( p- |$ w. k0 _3 B
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, H* q9 }5 I* n; v$ h/ SResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. % k5 v9 p+ `, a4 u# ^
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 610)
, ]( Z- w* f% M3 G3 r* O华为网盘附件：
4 U8 m4 k3 a' e9 _【华为网盘】ava.JPG
( s: v6 y4 `8 s1 w. \' J, X, [" w |
显身卡
